Carotid Intima-Media Thickness and Liver Histology in Hemodialysis Patients with Nonalcoholic Fatty Liver Disease

 

 Buy Article Permissions and Reprints

ABSTRACT

The prevalence of atherosclerotic cardiovascular disease in chronic hemodialysis (HD) patients has been demonstrated to be higher than in healthy people. Severe liver fibrosis is strongly associated with early carotid atherosclerosis and it might reduce the survival of patients who undergo both renal replacement therapy and transplantation. We wanted to assess whether nonalcoholic fatty liver disease (NAFLD) was associated with altered intima-media thickness (IMT) in HD patients as an independent marker of subclinical atherosclerosis. We enrolled 42 patients undergoing HD and 48 patients with normal renal function, all of them with high levels of aminotransferases and an ultrasonographic diagnosis of liver steatosis. The control group consisted of 60 healthy subjects. Laboratory tests for inflammatory and oxidative markers, ultrasonographic liver evaluation, carotid IMT measurement, and liver biopsy were performed. Different degrees of fibrosis were detected in our study cohort. Worse liver histopathological scores and higher plasmatic levels of C-reactive protein, reactive oxygen species, and vascular cell adhesion molecule-1 were found in HD patients. Carotid IMT was significantly higher (p < 0.005) in patients with histological steatosis. HD patients may develop active and progressive chronic hepatitis faster than patients with normal renal function and the thickness of their carotid intima-media might be markedly increased. These two conditions seem to be independent on classical risk factors and on metabolic syndrome. They might be related to the high levels of oxidants and to the inflammatory state, which are typical of patients undergoing HD. Independently related with the traditional risk factors for cardiovascular disease, nonspecific inflammation and oxide-reductive imbalance may play an important role in the progression of NAFLD and atherosclerotic disease in HD patients.

REFERENCES

• 1 Cheung A K, Sarnak M J, Yan G et al.. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients.  Kidney Int. 2000;  58 (1) 353-362
  CrossrefPubMedGoogle Scholar
• 2 Angulo P. Nonalcoholic fatty liver disease.  N Engl J Med. 2002;  346 (16) 1221-1231
  CrossrefPubMedGoogle Scholar
• 3 Clark J M, Brancati F L, Diehl A M. Nonalcoholic fatty liver disease.  Gastroenterology. 2002;  122 (6) 1649-1657
  CrossrefPubMedGoogle Scholar
• 4 Adinolfi L E, Gambardella M, Andreana A, Tripodi M F, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity.  Hepatology. 2001;  33 (6) 1358-1364
  CrossrefPubMedGoogle Scholar
• 5 Targher G, Bertolini L, Padovani R et al.. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease.  Diabetes Care. 2006;  29 (6) 1325-1330
  CrossrefPubMedGoogle Scholar
• 6 Benedetto F A, Mallamaci F, Tripepi G, Zoccali C. Prognostic value of ultrasonographic measurement of carotid intima media thickness in dialysis patients.  J Am Soc Nephrol. 2001;  12 (11) 2458-2464
  PubMedGoogle Scholar
• 7 Nishizawa Y, Shoji T, Maekawa K et al.. Intima-media thickness of carotid artery predicts cardiovascular mortality in hemodialysis patients.  Am J Kidney Dis. 2003;  41 (3, Suppl 1) S76-S79
  CrossrefPubMedGoogle Scholar
• 8 Kleiner D E, Brunt E M, Van Natta M et al.. Design and validation of a histological scoring system for non alcoholic fatty liver disease.  Hepatology. 2005;  4 1313-1321
  PubMedGoogle Scholar
• 9 Brunt E M. Nonalcoholic steatohepatitis.  Semin Liver Dis. 2004;  24 (1) 3-20
  Article in Thieme ConnectPubMedGoogle Scholar
• 10 American Diabetes Association . Diagnosis and classification of diabetes mellitus.  Diabetes Care. 2004;  27 (Suppl 1) S5-S10
  CrossrefPubMedGoogle Scholar
• 11 Macy E M, Hayes T E, Tracy R P. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications.  Clin Chem. 1997;  43 (1) 52-58
  PubMedGoogle Scholar
• 12 Fiotti N, Giansante C, Ponte E et al.. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease.  Atherosclerosis. 1999;  145 (1) 51-60
  CrossrefPubMedGoogle Scholar
• 13 Yagi K. Assay for serum lipid peroxide level and its chemical significance. In: Yagi K, ed. Lipid Peroxides in Biology and Medicine. New York: Academic Press; 1982: 223-242
  Google Scholar
• 14 Esterbauer H, Cheeseman K H. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal.  Methods Enzymol. 1990;  186 407-421
  PubMedGoogle Scholar
• 15 Paglia D E, Valentine W N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase.  J Lab Clin Med. 1967;  70 (1) 158-169
  PubMedGoogle Scholar
• 16 Matthews D R, Hosker J P, Rudenski A S, Naylor B A, Treacher D F, Turner R C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 (7) 412-419
  Google Scholar
• 17 Haffner S M, Miettinen H, Stern M P. The homeostasis model in the San Antonio Heart Study.  Diabetes Care. 1997;  20 (7) 1087-1092
  CrossrefPubMedGoogle Scholar
• 18 World Health Organization .AUDIT. The Alcohol Use Disorders Identification Test: Guidelines for Use in Primary Health Care. Genève, Switzerland: WHO; 1992
  Google Scholar
• 19 O'Leary D H, Polak J F. Intima-media thickness: a tool for atherosclerosis imaging and event prediction.  Am J Cardiol. 2002;  90 (10C) 18L-21L
  CrossrefPubMedGoogle Scholar
• 20 Cortez-Pinto H, de Moura M C, Day C P. Non-alcoholic steatohepatitis: from cell biology to clinical practice.  J Hepatol. 2006;  44 (1) 197-208
  CrossrefPubMedGoogle Scholar
• 21 Targher G, Bertolini L, Padovani R et al.. Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease.  Diabet Med. 2006;  23 (4) 403-409
  CrossrefPubMedGoogle Scholar
• 22 Targher G, Bertolini L, Padovani R, Rodella S, Arcaro G, Day C. Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C.  J Hepatol. 2007;  46 (6) 1126-1132
  CrossrefPubMedGoogle Scholar
• 23 Stenvinkel P, Heimbürger O, Paultre F et al.. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure.  Kidney Int. 1999;  55 (5) 1899-1911
  CrossrefPubMedGoogle Scholar
• 24 Chen J, Muntner P, Hamm L L et al.. The metabolic syndrome and chronic kidney disease in U.S. adults.  Ann Intern Med. 2004;  140 (3) 167-174
  PubMedGoogle Scholar
• 25 Seki S, Kitada T, Sakagushi H, Katani K, Wakasa K. In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver disease.  J Hepatol. 2002;  37 (1) 56-62
  CrossrefPubMedGoogle Scholar
• 26 Chalasani N, Deeg M A, Crabb D W. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis.  Am J Gastroenterol. 2004;  99 (8) 1497-1502
  CrossrefPubMedGoogle Scholar
• 27 Volzke H, Robinson D M, Kleine V et al.. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis.  World J Gastroenterol. 2005;  11 (12) 1848-1853
  CrossrefPubMedGoogle Scholar
• 28 Bressler P, Bailey S R, Matsuda M, DeFronzo R A. Insulin resistance and coronary artery disease.  Diabetologia. 1996;  39 (11) 1345-1350
  CrossrefPubMedGoogle Scholar

Sergio NeriM.D. 

Department of Internal Medicine and Systemic Diseases, Policlinico di Catania

Via S. Sofia 87, 95123 Catania, Italy

Email: sergio.neri4@tin.it